Clinical Evaluation of the Efficacy and Safety of a Medical Device in the Form of Rectal Suppositories (Prospidol®) for the Treatment of Symptoms Associated With Chronic Prostatitis/Chronic Pelvic Pain Syndrome.

Inclusion Criteria: * male subjects aged between 18 and 60; * clinical presentation typical of prostatitis and a clinical diagnosis of chronic prostatitis type IIIa or IIIb (CP/CPPS) for at least 3 months; * no treatment for at least 2 months; * PSA \< 3 ng/mL; * digital rectal examination negative for nodules or BPH; * negative microbiological tests on urine and seminal fluid; * baseline score on the validated Italian version of the NIH-CPSI pain domain questionnaire \> 7 or total NIH-CPSI score \> 15; * digital rectal examination not suggestive of prostate cancer. Exclusion Criteria: * patients with signs of infection and a PSA level \> 3 ng/ml; * other active prostate conditions; * patients with active neoplastic, neurodegenerative or immunological conditions, those who are immunocompromised, or those who are already taking supplements or functional foods for any reason; * patients undergoing treatment with systemic or topical corticosteroids; * patients who will not sign the informed consent form; * patients unable to participate in a clinical trial for any reason (e.g. psychiatric patients, those with cancer, on dialysis, or with severe liver or kidney failure); * patients with allergies to any of the components of the medical device (MD) under investigation.